Skip to main content
GRALGRAIL, Inc.Sell5.2·$120.30

GRAIL (GRAL) Q3 2026 earnings — TrendMatrix coverage

BEAT+257.9% vs estimateEPS $3.00 vs -$1.90 estCurrent verdict Sell 5.2/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy

Event detail · Q3 2026

Key numbers

Adjusted EPS
$3.00
Estimate
-$1.90
Surprise
+257.9%
Score today
5.2/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q3 2026

How the report landed

GRAIL (GRAL) beat the -$1.90 estimate with adjusted EPS of $3.00 — a large 257.9% upside surprise.

Around the report

Coverage in the report window

  • RBC Capital Maintains Sector Perform on GRAIL, Raises Price Target to $100 — benzinga, 2026-11-05
  • RBC Raises Price Target on GRAIL, Inc. — fiscal.ai, 2026-11-05
  • GRAIL, Inc. 12-Month Price Target Raised to $134.33 — fiscal.ai, 2026-11-05
Current read · as of 2026-11-06

Where TrendMatrix's rating stands now

TrendMatrix currently rates GRAL Sell at 5.2/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +257.9% surprise compares with a +84.1% four-quarter average. Next scheduled report: 2027-02-18.

What argues against it

  • Concentration risk — Product: Galleri
  • Concentration risk — Pipeline: Galleri PMA
  • Target reached (-4.1% upside)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$120.30
Stop
$113.49

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare context

GRAL at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$5.32B
P/E (fwd)
-14.4
52-week range
$41.50–$166.47
Off 52-week high
27.7%
RSI (14)
49
Volume vs avg
0.40×
Score today
5.2/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home › Stocks › GRAL › Earnings › Q3 2026 earnings